FDA Expands GSK RSV Vaccine to Younger At-Risk Adults
GSK plc has announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to include adults aged 18…
Read More...
Read More...
